| 1256 | Humans (MeSH) |
| 624 | Influenza, Human (epidemiology) |
| 583 | Female (MeSH) |
| 517 | Male (MeSH) |
| 509 | Influenza, Human (prevention & control) |
| 473 | Adult (MeSH) |
| 429 | Middle Aged (MeSH) |
| 400 | Canada (MeSH) |
| 399 | Aged (MeSH) |
| 377 | Canada (epidemiology) |
| 359 | Adolescent (MeSH) |
| 337 | Child (MeSH) |
| 284 | Child, Preschool (MeSH) |
| 239 | Influenza Vaccines (administration & dosage) |
| 237 | Infant (MeSH) |
| 216 | Young Adult (MeSH) |
| 209 | Influenza, Human (virology) |
| 207 | Animals (MeSH) |
| 174 | Disease Outbreaks (MeSH) |
| 166 | Ontario (epidemiology) |
| 164 | Influenza A Virus, H1N1 Subtype (MeSH) |
| 155 | Seasons (MeSH) |
| 155 | Aged, 80 and over (MeSH) |
| 138 | Ontario (MeSH) |
| 114 | Risk Factors (MeSH) |
| 110 | Influenza Vaccines (immunology) |
| 110 | Infant, Newborn (MeSH) |
| 109 | Disease Outbreaks (prevention & control) |
| 99 | Influenza A virus (isolation & purification) |
| 95 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
| 92 | Vaccination (statistics & numerical data) |
| 90 | Influenza Vaccines (adverse effects) |
| 89 | Retrospective Studies (MeSH) |
| 88 | Surveys and Questionnaires (MeSH) |
| 88 | Incidence (MeSH) |
| 86 | Pandemics (MeSH) |
| 84 | Influenza, Human (diagnosis) |
| 81 | Influenza A Virus, H1N1 Subtype (immunology) |
| 80 | Influenza Vaccines (therapeutic use) |
| 79 | Influenza, Human (immunology) |
| 73 | Influenza Vaccines (MeSH) |
| 70 | Population Surveillance (MeSH) |
| 70 | Hospitalization (statistics & numerical data) |
| 70 | Antiviral Agents (therapeutic use) |
| 70 | Age Factors (MeSH) |
| 69 | Pregnancy (MeSH) |
| 68 | Time Factors (MeSH) |
| 64 | Vaccination (MeSH) |
| 63 | United States (MeSH) |
| 63 | Influenza, Human (transmission) |
| 63 | Influenza, Human (drug therapy) |
| 58 | Cross-Sectional Studies (MeSH) |
| 56 | Influenza, Human (mortality) |
| 55 | Orthomyxoviridae Infections (veterinary) |
| 55 | Influenza in Birds (epidemiology) |
| 54 | Influenza A virus (immunology) |
| 53 | Prospective Studies (MeSH) |
| 52 | Phylogeny (MeSH) |
| 51 | Health Knowledge, Attitudes, Practice (MeSH) |
| 50 | Swine (MeSH) |
| 50 | Alberta (MeSH) |
| 49 | Influenza, Human (therapy) |
| 48 | Quebec (MeSH) |
| 48 | Pandemics (prevention & control) |
| 48 | Influenza A virus (MeSH) |
| 46 | Influenza B virus (isolation & purification) |
| 45 | Treatment Outcome (MeSH) |
| 45 | Quebec (epidemiology) |
| 45 | Influenza, Human (complications) |
| 45 | Cohort Studies (MeSH) |
| 45 | Case-Control Studies (MeSH) |
| 44 | Influenza in Birds (virology) |
| 44 | Hemagglutination Inhibition Tests (MeSH) |
| 43 | Sentinel Surveillance (MeSH) |
| 43 | Antibodies, Viral (blood) |
| 42 | Prevalence (MeSH) |
| 42 | Population Surveillance (methods) |
| 42 | Influenza A virus (genetics) |
| 41 | Orthomyxoviridae Infections (epidemiology) |
| 41 | Influenza A virus (classification) |
| 39 | Disease Outbreaks (veterinary) |
| 39 | Age Distribution (MeSH) |
| 38 | Hospitalization (MeSH) |
| 37 | Risk Assessment (MeSH) |
| 37 | Respiratory Tract Infections (epidemiology) |
| 36 | Attitude of Health Personnel (MeSH) |
| 35 | Sequence Analysis, DNA (MeSH) |
| 35 | Molecular Sequence Data (MeSH) |
| 35 | Logistic Models (MeSH) |
| 34 | Influenza A Virus, H1N1 Subtype (genetics) |
| 33 | Orthomyxoviridae Infections (virology) |
| 33 | Manitoba (epidemiology) |
| 33 | Immunization Programs (MeSH) |
| 33 | Health Personnel (MeSH) |
| 33 | Alberta (epidemiology) |
| 32 | British Columbia (MeSH) |
| 31 | United States (epidemiology) |
| 31 | Swine Diseases (virology) |
| 31 | Public Health (MeSH) |
| 31 | British Columbia (epidemiology) |
| 30 | History, 20th Century (MeSH) |
| 29 | Orthomyxoviridae (isolation & purification) |
| 29 | Immunization Programs (statistics & numerical data) |
| 28 | Swine Diseases (epidemiology) |
| 28 | Influenza B virus (immunology) |
| 28 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
| 28 | Amantadine (therapeutic use) |
| 27 | Risk (MeSH) |
| 27 | Respiratory Tract Infections (virology) |
| 27 | Influenza, Human (history) |
| 27 | Comorbidity (MeSH) |
| 26 | Socioeconomic Factors (MeSH) |
| 26 | RNA, Viral (genetics) |
| 26 | Models, Theoretical (MeSH) |
| 26 | Influenza B virus (MeSH) |
| 26 | Influenza A Virus, H3N2 Subtype (MeSH) |
| 26 | Health Policy (MeSH) |
| 26 | Cost-Benefit Analysis (MeSH) |
| 25 | Influenza Vaccines (economics) |
| 25 | Birds (MeSH) |
| 24 | Sensitivity and Specificity (MeSH) |
| 24 | Influenza Vaccines (supply & distribution) |
| 23 | Long-Term Care (MeSH) |
| 23 | Influenza A virus (pathogenicity) |
| 23 | Influenza A Virus, H3N2 Subtype (immunology) |
| 23 | Emergency Service, Hospital (statistics & numerical data) |
| 22 | Vaccination (methods) |
| 21 | Severity of Illness Index (MeSH) |
| 21 | Practice Guidelines as Topic (MeSH) |
| 21 | Manitoba (MeSH) |
| 21 | Influenza A Virus, H3N2 Subtype (genetics) |
| 20 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 20 | Qualitative Research (MeSH) |
| 20 | Pandemics (statistics & numerical data) |
| 20 | Nursing Homes (MeSH) |
| 20 | Models, Statistical (MeSH) |
| 20 | Influenza, Human (microbiology) |
| 20 | Disease Outbreaks (statistics & numerical data) |
| 20 | Disaster Planning (organization & administration) |
| 20 | Cross Infection (prevention & control) |
| 19 | Sex Factors (MeSH) |
| 19 | Severe Acute Respiratory Syndrome (epidemiology) |
| 19 | Odds Ratio (MeSH) |
| 19 | Influenza in Birds (transmission) |
| 19 | Infection Control (methods) |
| 19 | Cross Infection (epidemiology) |
| 18 | Outcome Assessment, Health Care (MeSH) |
| 18 | Oseltamivir (therapeutic use) |
| 18 | Influenza, Human (economics) |
| 18 | Immunization Programs (organization & administration) |
| 18 | Decision Making (MeSH) |
| 18 | Attitude to Health (MeSH) |
| 17 | Vaccines, Inactivated (immunology) |
| 17 | Seroepidemiologic Studies (MeSH) |
| 17 | Respiratory Tract Diseases (epidemiology) |
| 17 | Reproducibility of Results (MeSH) |
| 17 | Program Evaluation (MeSH) |
| 17 | Pregnancy Complications, Infectious (prevention & control) |
| 17 | Patient Acceptance of Health Care (MeSH) |
| 17 | Interviews as Topic (MeSH) |
| 17 | Influenza, Human (MeSH) |
| 17 | Influenza B virus (genetics) |
| 17 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
| 17 | Immunization Schedule (MeSH) |
| 17 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
| 17 | Health Surveys (MeSH) |
| 17 | Health Care Surveys (MeSH) |
| 17 | Disease Outbreaks (history) |
| 17 | Absenteeism (MeSH) |
| 16 | Travel (MeSH) |
| 16 | Rural Population (MeSH) |
| 16 | Pilot Projects (MeSH) |
| 16 | National Health Programs (MeSH) |
| 16 | Multivariate Analysis (MeSH) |
| 16 | Europe (MeSH) |
| 16 | Epidemiological Monitoring (MeSH) |
| 16 | Data Collection (MeSH) |
| 16 | Computer Simulation (MeSH) |
| 15 | Viral Proteins (genetics) |
| 15 | Vaccines, Inactivated (administration & dosage) |
| 15 | Vaccination (standards) |
| 15 | Vaccination (psychology) |
| 15 | Pneumococcal Infections (prevention & control) |
| 15 | Orthomyxoviridae (immunology) |
| 15 | Models, Biological (MeSH) |
| 15 | Influenza, Human (ethnology) |
| 15 | Influenza in Birds (prevention & control) |
| 15 | Immunization (MeSH) |
| 15 | Follow-Up Studies (MeSH) |
| 15 | Europe (epidemiology) |
| 15 | Epidemics (MeSH) |
| 15 | Drug Resistance, Viral (MeSH) |
| 15 | Disaster Planning (MeSH) |
| 14 | Poultry Diseases (epidemiology) |
| 14 | Pneumonia (epidemiology) |
| 14 | Neuraminidase (genetics) |
| 14 | Intensive Care Units (MeSH) |
| 14 | Immunization Programs (standards) |
| 14 | Health Behavior (MeSH) |
| 14 | Databases, Factual (MeSH) |
| 14 | Adjuvants, Immunologic (administration & dosage) |
| 13 | Urban Population (MeSH) |
| 13 | Syndrome (MeSH) |
| 13 | Respiratory Tract Diseases (etiology) |
| 13 | Pregnancy Complications, Infectious (epidemiology) |
| 13 | Patient Compliance (MeSH) |
| 13 | Nasopharynx (virology) |
| 13 | Internet (MeSH) |
| 13 | Influenza, Human (pathology) |
| 13 | Influenza B virus (classification) |
| 13 | Indians, North American (statistics & numerical data) |
| 13 | Immunization (statistics & numerical data) |
| 13 | Horses (MeSH) |
| 13 | Health Planning (MeSH) |
| 13 | Communicable Diseases (epidemiology) |
| 13 | Communicable Disease Control (methods) |
| 13 | Acute Disease (MeSH) |
| 12 | Vaccination (adverse effects) |
| 12 | United Kingdom (MeSH) |
| 12 | Registries (MeSH) |
| 12 | Poultry (MeSH) |
| 12 | Orthomyxoviridae Infections (transmission) |
| 12 | Orthomyxoviridae (classification) |
| 12 | Nova Scotia (MeSH) |
| 12 | Neutralization Tests (MeSH) |
| 12 | Influenza A Virus, H1N1 Subtype (classification) |
| 12 | Health Status (MeSH) |
| 12 | Health Services Accessibility (MeSH) |
| 12 | Focus Groups (MeSH) |
| 12 | Community-Acquired Infections (epidemiology) |
| 12 | Antigens, Viral (immunology) |
| 12 | Antigens, Viral (analysis) |
| 12 | Animals, Wild (virology) |
| 11 | Workforce (MeSH) |
| 11 | Turkeys (MeSH) |
| 11 | Species Specificity (MeSH) |
| 11 | Schools (MeSH) |
| 11 | Public Health Administration (MeSH) |
| 11 | Poultry Diseases (virology) |
| 11 | Oseltamivir (MeSH) |
| 11 | Orthomyxoviridae (MeSH) |
| 11 | Linear Models (MeSH) |
| 11 | Length of Stay (MeSH) |
| 11 | Influenza A Virus, H5N1 Subtype (MeSH) |
| 11 | Health Personnel (psychology) |
| 11 | Genotype (MeSH) |
| 11 | Cluster Analysis (MeSH) |
| 11 | Chronic Disease (MeSH) |
| 11 | Base Sequence (MeSH) |
| 11 | Antiviral Agents (administration & dosage) |
| 11 | Animals, Wild (MeSH) |
| 10 | Virus Diseases (virology) |
| 10 | Virus Diseases (epidemiology) |
| 10 | Vaccination (economics) |
| 10 | Sex Distribution (MeSH) |
| 10 | Severe Acute Respiratory Syndrome (prevention & control) |
| 10 | Respiratory Tract Infections (veterinary) |
| 10 | Respiratory Tract Infections (diagnosis) |
| 10 | Residence Characteristics (MeSH) |
| 10 | Regression Analysis (MeSH) |
| 10 | Public Opinion (MeSH) |
| 10 | Polymerase Chain Reaction (MeSH) |
| 10 | Patient Selection (MeSH) |
| 10 | Patient Acceptance of Health Care (statistics & numerical data) |
| 10 | Nova Scotia (epidemiology) |
| 10 | Mutation (MeSH) |
| 10 | Longitudinal Studies (MeSH) |
| 10 | Influenza, Human (psychology) |
| 10 | Influenza Vaccines (standards) |
| 10 | Influenza A Virus, H5N1 Subtype (genetics) |
| 10 | Influenza A Virus, H1N1 Subtype (drug effects) |
| 10 | Indians, North American (MeSH) |
| 10 | History, 21st Century (MeSH) |
| 10 | Health Personnel (statistics & numerical data) |
| 10 | Global Health (MeSH) |
| 10 | Family Practice (MeSH) |
| 10 | Eye Diseases (etiology) |
| 10 | Emergency Service, Hospital (MeSH) |
| 10 | Ducks (virology) |
| 10 | Contraindications (MeSH) |
| 10 | Confidence Intervals (MeSH) |
| 10 | Communication (MeSH) |
| 10 | Birds (virology) |
| 10 | Antiviral Agents (pharmacology) |
| 10 | Antibodies, Viral (analysis) |
| 10 | Anti-Bacterial Agents (therapeutic use) |
| 10 | Amino Acid Sequence (MeSH) |
| 9 | Virulence (MeSH) |
| 9 | Vaccines, Inactivated (adverse effects) |
| 9 | Reassortant Viruses (genetics) |
| 9 | Public Health Practice (MeSH) |
| 9 | Pneumonia, Viral (epidemiology) |
| 9 | Pneumonia (mortality) |
| 9 | Patient Admission (statistics & numerical data) |
| 9 | Intensive Care Units (statistics & numerical data) |
| 9 | Influenza, Human (etiology) |
| 9 | Immunization Programs (economics) |
| 9 | Horse Diseases (epidemiology) |
| 9 | Health Services Research (MeSH) |
| 9 | Genome, Viral (MeSH) |
| 9 | Data Collection (methods) |
| 9 | Critical Illness (MeSH) |
| 9 | Complement Fixation Tests (MeSH) |
| 9 | Communicable Disease Control (MeSH) |
| 9 | Clinical Trials as Topic (MeSH) |
| 9 | Animal Migration (MeSH) |
| 9 | Algorithms (MeSH) |
| 8 | Zanamivir (MeSH) |
| 8 | Serologic Tests (MeSH) |
| 8 | Saskatchewan (epidemiology) |
| 8 | Pyrans (MeSH) |
| 8 | Prognosis (MeSH) |
| 8 | Pregnancy Complications, Infectious (virology) |
| 8 | Patient Education as Topic (MeSH) |
| 8 | Patient Admission (MeSH) |
| 8 | Organizational Policy (MeSH) |
| 8 | Newfoundland and Labrador (epidemiology) |
| 8 | Neuraminidase (antagonists & inhibitors) |
| 8 | Mortality (MeSH) |
| 8 | Mice (MeSH) |
| 8 | Information Dissemination (MeSH) |
| 8 | Influenza, Human (physiopathology) |
| 8 | Influenza A Virus, H3N2 Subtype (classification) |
| 8 | Hospitalization (trends) |
| 8 | Health Services Needs and Demand (MeSH) |
| 8 | Guanidines (MeSH) |
| 8 | Genes, Viral (MeSH) |
| 8 | Family Characteristics (MeSH) |
| 8 | Evidence-Based Medicine (MeSH) |
| 8 | Electronic Health Records (MeSH) |
| 8 | Disease Outbreaks (economics) |
| 8 | Costs and Cost Analysis (MeSH) |
| 8 | Cooperative Behavior (MeSH) |
| 8 | Chickens (MeSH) |
| 8 | Cell Line (MeSH) |
| 8 | Antiviral Agents (adverse effects) |
| 8 | Antibodies, Viral (immunology) |
| 7 | World Health Organization (MeSH) |
| 7 | Viruses (isolation & purification) |
| 7 | Swine Diseases (transmission) |
| 7 | Survival Analysis (MeSH) |
| 7 | Sialic Acids (therapeutic use) |
| 7 | Serotyping (MeSH) |
| 7 | Sentinel Surveillance (veterinary) |
| 7 | Respiratory Syncytial Virus Infections (epidemiology) |
| 7 | Real-Time Polymerase Chain Reaction (MeSH) |
| 7 | Randomized Controlled Trials as Topic (MeSH) |
| 7 | Quality of Life (MeSH) |
| 7 | Public Health Surveillance (MeSH) |
| 7 | Primary Health Care (MeSH) |
| 7 | Pregnancy Outcome (MeSH) |
| 7 | Predictive Value of Tests (MeSH) |
| 7 | Practice Patterns, Physicians' (statistics & numerical data) |
| 7 | Poultry (virology) |
| 7 | Pneumonia, Pneumococcal (prevention & control) |
| 7 | Pneumococcal Vaccines (administration & dosage) |
| 7 | Pneumococcal Infections (epidemiology) |
| 7 | Office Visits (statistics & numerical data) |
| 7 | Nurse's Role (MeSH) |
| 7 | Needs Assessment (MeSH) |
| 7 | Mutation, Missense (MeSH) |
| 7 | Military Personnel (MeSH) |
| 7 | Mass Vaccination (statistics & numerical data) |
| 7 | International Cooperation (MeSH) |
| 7 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
| 7 | Influenza A Virus, H1N1 Subtype (physiology) |
| 7 | Infection Control (organization & administration) |
| 7 | Hospitals, Pediatric (MeSH) |
| 7 | Hospitals (statistics & numerical data) |
| 7 | Hemagglutinin Glycoproteins, Influenza Virus (immunology) |
| 7 | Health Promotion (MeSH) |
| 7 | Genetic Variation (MeSH) |
| 7 | Evolution, Molecular (MeSH) |
| 7 | Ducks (microbiology) |
| 7 | Drug Utilization (MeSH) |
| 7 | Drug Combinations (MeSH) |
| 7 | Dogs (MeSH) |
| 7 | Disease Transmission, Infectious (prevention & control) |
| 7 | Demography (MeSH) |
| 7 | Critical Care (MeSH) |
| 7 | Cost of Illness (MeSH) |
| 7 | Clinical Laboratory Techniques (MeSH) |
| 7 | Chickens (virology) |
| 7 | Asthma (epidemiology) |
| 7 | Antiviral Agents (supply & distribution) |
| 7 | Analysis of Variance (MeSH) |
| 7 | Alaska (epidemiology) |
| 7 | Acetamides (therapeutic use) |
| 6 | Zoonoses (MeSH) |
| 6 | Yukon Territory (epidemiology) |
| 6 | World War I (MeSH) |
| 6 | Vaccine Potency (MeSH) |
| 6 | Urban Health (MeSH) |
| 6 | Universities (MeSH) |
| 6 | Telephone (MeSH) |
| 6 | Squalene (administration & dosage) |
| 6 | Safety (MeSH) |
| 6 | Risk Assessment (methods) |
| 6 | Respiratory Tract Infections (prevention & control) |
| 6 | Respiratory Tract Infections (microbiology) |
| 6 | Respiratory Tract Infections (drug therapy) |
| 6 | Respiration, Artificial (MeSH) |
| 6 | Research Design (MeSH) |
| 6 | Reassortant Viruses (isolation & purification) |
| 6 | Public Health Surveillance (methods) |
| 6 | Public Health (methods) |
| 6 | Preventive Health Services (statistics & numerical data) |
| 6 | Practice Patterns, Physicians' (MeSH) |
| 6 | Polysorbates (administration & dosage) |
| 6 | Policy Making (MeSH) |
| 6 | Pneumonia, Viral (veterinary) |
| 6 | Pneumonia, Pneumococcal (epidemiology) |
| 6 | Physicians (MeSH) |
| 6 | Oseltamivir (administration & dosage) |
| 6 | Nose (virology) |
| 6 | Neuraminidase (immunology) |
| 6 | Motivation (MeSH) |
| 6 | Models, Economic (MeSH) |
| 6 | Masks (MeSH) |
| 6 | Influenza A virus (physiology) |
| 6 | Influenza A Virus, H5N2 Subtype (isolation & purification) |
| 6 | Influenza A Virus, H5N1 Subtype (isolation & purification) |
| 6 | Influenza A Virus, H3N2 Subtype (pathogenicity) |
| 6 | Hospitals (MeSH) |
| 6 | Homes for the Aged (MeSH) |
| 6 | History, 19th Century (MeSH) |
| 6 | Health Facilities (MeSH) |
| 6 | Guidelines as Topic (MeSH) |
| 6 | Geography (MeSH) |
| 6 | Family Practice (statistics & numerical data) |
| 6 | Eye Diseases (epidemiology) |
| 6 | Emergency Service, Hospital (organization & administration) |
| 6 | Drug-Related Side Effects and Adverse Reactions (epidemiology) |
| 6 | Disease Reservoirs (veterinary) |
| 6 | Disease Reservoirs (MeSH) |
| 6 | Disease Outbreaks (epidemiology) |
| 6 | Communicable Diseases, Emerging (epidemiology) |
| 6 | Australia (MeSH) |
| 6 | Asthma (complications) |
| 6 | Antiviral Agents (economics) |
| 6 | Antigens, Viral (genetics) |
| 6 | Antigenic Variation (MeSH) |
| 6 | Aging (MeSH) |
| 6 | Advisory Committees (MeSH) |
| 6 | Adjuvants, Immunologic (adverse effects) |
| 5 | alpha-Tocopherol (administration & dosage) |
| 5 | Zanamivir (therapeutic use) |
| 5 | Viral Load (MeSH) |
| 5 | Vaccines (administration & dosage) |
| 5 | Turkeys (virology) |
| 5 | Triage (methods) |
| 5 | Triage (MeSH) |
| 5 | Temperature (MeSH) |
| 5 | Swine Diseases (microbiology) |
| 5 | Swine Diseases (immunology) |
| 5 | Swine (virology) |
| 5 | Streptococcus pneumoniae (isolation & purification) |
| 5 | Social Class (MeSH) |
| 5 | Skilled Nursing Facilities (MeSH) |
| 5 | Sequence Homology (MeSH) |
| 5 | Self Report (MeSH) |
| 5 | Self Care (methods) |
| 5 | Rhinovirus (isolation & purification) |
| 5 | Respiratory Tract Infections (mortality) |
| 5 | Respiratory Tract Infections (etiology) |
| 5 | Respiratory Tract Infections (MeSH) |
| 5 | Residence Characteristics (statistics & numerical data) |
| 5 | Recurrence (MeSH) |
| 5 | Reassortant Viruses (MeSH) |
| 5 | Quality-Adjusted Life Years (MeSH) |
| 5 | Public Health Administration (methods) |
| 5 | Primary Health Care (statistics & numerical data) |
| 5 | Prenatal Care (MeSH) |
| 5 | Premature Birth (epidemiology) |
| 5 | Population Density (MeSH) |
| 5 | Poisson Distribution (MeSH) |
| 5 | Pneumonia, Viral (virology) |
| 5 | Pneumococcal Vaccines (MeSH) |
| 5 | Physicians, Family (MeSH) |
| 5 | Paramyxoviridae Infections (virology) |
| 5 | Paramyxoviridae Infections (epidemiology) |
| 5 | Paramyxoviridae Infections (MeSH) |
| 5 | Orthomyxoviridae Infections (prevention & control) |
| 5 | Orthomyxoviridae Infections (microbiology) |
| 5 | Orthomyxoviridae Infections (immunology) |
| 5 | Orthomyxoviridae Infections (diagnosis) |
| 5 | Orthomyxoviridae (genetics) |
| 5 | Organizational Case Studies (MeSH) |
| 5 | Military Medicine (MeSH) |
| 5 | Microbial Sensitivity Tests (MeSH) |
| 5 | Mexico (epidemiology) |
| 5 | Mass Vaccination (MeSH) |
| 5 | Mass Screening (MeSH) |
| 5 | Mass Media (MeSH) |
| 5 | Mandatory Programs (MeSH) |
| 5 | Lung (pathology) |
| 5 | Laboratories (MeSH) |
| 5 | Influenza, Human (classification) |
| 5 | Influenza Vaccines (pharmacology) |
| 5 | Influenza B virus (drug effects) |
